Vanguard realignment leads to separate reports for Roivant (ROIV)
Rhea-AI Filing Summary
Roivant Sciences Ltd ownership disclosure: The Vanguard Group filed an amendment reporting 0 shares and 0% beneficial ownership of Roivant common stock. The filing explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report holdings separately in reliance on SEC Release No. 34-39538.
The filing is a routine ownership update reflecting disaggregated reporting by Vanguard entities rather than an acquisition or disposition of Roivant shares.
Positive
- None.
Negative
- None.
Insights
Vanguard reports no beneficial ownership after internal realignment.
The filing lists 0 shares and 0% ownership as of the amendment date, indicating no direct or shared voting or dispositive power over Roivant common stock in this report. The disclosure includes a statement that Vanguard subsidiaries will report separately following an internal realignment effective January 12, 2026.
Cash-flow treatment and any subsidiary-level holdings are not detailed in the excerpt; subsequent 13G/A entries from Vanguard entities may show holdings if present.
FAQ
What does Roivant (ROIV) Schedule 13G/A from Vanguard report?
Why does Vanguard mention SEC Release No. 34-39538 in the ROIV filing?
Who signed the ROIV Schedule 13G/A amendment for Vanguard?
Will this amendment show Vanguard's subsidiary holdings in ROIV?